Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Menu
Topics in Antiviral Medicine
™
February 2026
Volume 34, Issue 1
Download here
, or select individual articles
Special Issue: Abstracts From the 2026 Conference on Retroviruses and Opportunistic Infections
Abstracts
Topics in Antiviral Medicine™
Current Issues
Previous Issues
TAM
Policies and Practices
TAM
Author and Contributor Guidelines
Topics in Antiviral Medicine
Editorial Board
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Practice Question of the Week
April 20, 2026: Optimal Management of Infant Postnatal HIV Prophylaxis
A woman who is pregnant for the first time delivers a healthy infant at 38 weeks' gestation. When she presented for prenatal care at 15 weeks, her HIV RNA level was 5000 copies/mL. After antiretroviral therapy (ART) adherence improved, her HIV RNA level subsequently decreased to 890 copies/mL by 25 weeks' gestation. From 30 weeks through 36 weeks, she had an HIV RNA level below the limit of detection. Which of the following statements describes the optimal management of the infant’s postnatal HIV prophylaxis?
A. Birth HIV nucleic acid testing (NAT) plus a 3-drug ART presumptive treatment for 4 to 8 weeks
B. Nevirapine prophylaxis for 4 to 6 weeks
C. Birth HIV NAT plus zidovudine (ZDV)/raltegravir for 4 weeks
D. Birth HIV NAT plus ZDV/nevirapine for 4 weeks with deescalation to ZDV alone at 4 weeks if birth NAT is negative
E. Birth HIV NAT plus a 3-drug ART presumptive treatment with deescalation to ZDV alone to complete 2 to 6 weeks total of ZDV if HIV NAT is negative
View the Presentation
View the On-Demand Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE
